Mirabegron

Phase 3

Astellas Pharma (ALPMY)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Neurogenic Detrusor Overactivity

View Full Landscape

Drug Information

Target Indication

Neurogenic Detrusor Overactivity

Clinical Trial

NCT02751931

Last updated: 12/23/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA12/20/2012

Betmiga

Overactive bladder in adults Betmiga prolonged-release tablets are indicated for symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome. Neurogenic detrusor overactivity in the paediatric population Betmiga prolonged release tablets are indicated for treatment of neurogenic detrusor overactivity (NDO) in paediatric patients aged 3 to less than 18 years.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

ALPMY

Astellas Pharma

Healthcare•North America•NASDAQ

Related Pipeline

OPT-80Phase 3

Clostridium Difficile

daclizumabPhase 3

Kidney Transplantation